MedTrace Logo

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

NCT06168929 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-01-23

No results posted yet for this study

Summary

The study is being conducted to evaluate the pharmacokinetic, and safety of two sizes of SHR4640 tablets in healthy adults, to explore the bioequivalence between two sizes of SHR4640 tablets.

Conditions

  • Hyperuricemia

Interventions

DRUG

SHR4640

SHR4640, 2.5mg\*4 - 10mg\*1

DRUG

SHR4640

SHR4640, 10mg\*1 - 2.5mg\*4

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-13
Primary Completion
2024-01-13
Completion
2024-01-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06168929 on ClinicalTrials.gov